Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

The National Institutes of Health (NIH) is preparing to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) for the Clinical and Translational Science Award (CTSA) Program, specifically the Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). This funding opportunity aims to foster meaningful collaborations and innovative projects in clinical and translational science, with a focus on enhancing health outcomes. The estimated total program funding is $5 million, with an award ceiling of $650,000, and the application process is expected to open in Fall 2024, with submissions due in Winter 2025. Interested applicants, particularly for-profit organizations, should prepare for the anticipated timeline and review the CCIA webpage for further details.